358
Participants
Start Date
March 27, 2017
Primary Completion Date
July 27, 2018
Study Completion Date
July 27, 2018
TNX-102 SL
Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
Placebo SL Tablet
Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
New York, New York
Cedarhurst, Cedarhurst
Media, Media
Downingtown, Downingtown
Washington, D.C., Washington D.C.
Salem, Salem
Charleston, Charleston
Atlanta, Atlanta
Jacksonville, Jacksonville
Lake City, Lake City
Maitland, Maitland
Lauderhill, Lauderhill
Tampa, Tampa
Flowood, Flowood
Canton, Canton
Cincinnati, Cincinnati
Dayton, Dayton
Missoula, Missoula
Chicago, Chicago
St. Louis, St Louis
Little Rock, Little Rock
Rogers, Rogers
Oklahoma City, Oklahoma City
Dallas, Dallas
Houston, Houston
San Antonio, San Antonio
Austin, Austin
Colorado Springs, Colorado Springs
Phoenix, Phoenix
Las Vegas, Las Vegas
Beverly hills, Beverly Hills
Glendale, Glendale
Oceanside, Oceanside
San Diego, San Diego
San Diego, San Diego
Riverside, Riverside
Temecula, Temecula
Orange, Orange
Oakland, Oakland
Everett, Everett
Cromwell, Cromwell
Norwich, Norwich
New Bedford, New Bedford
Berlin, Berlin
Collaborators (1)
Premier Research Group plc
UNKNOWN
Tonix Pharmaceuticals, Inc.
INDUSTRY